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Dr. Cheryl Oncken is studying the
connection between exercise and
smoking cessation.

Dean’s Message

American Cancer Society
Supports Taylor’s
Bladder Cancer Research

W

elcome to the first issue
of our new publication.
Designed to be a quick
and easy read, our goal is to
convey the energy and passion
found throughout the dynamic
University of Connecticut
School of Medicine.
I became the seventh dean of
the UConn School of Medicine
and vice president for Health
Affairs at the UConn Health
Center just a year ago. I joined
the UConn community from
the University of Virginia,
where I served as the Lillian T.

Pratt Distinguished Professor
and chair of the Department of
Orthopaedic Surgery.
Since my arrival, I have
been continually impressed
with the quality and intellectual
vigor of our medical school
faculty, students and alumni.
Three times a year, these pages
will highlight just some of the
extraordinary accomplishments
and talents of these people.
We will share their stories and
describe the impact they are
having both here in Connecticut
and well beyond.

Grant from Gates Foundation’s
Grand Challenges
Explorations Initiative

A

rthur Günzl, Ph.D., associate professor
in the Department of Genetics and
Developmental Biology, is the first Health Center
researcher to be awarded a grant by the Bill and Melinda Gates
Foundation. Günzl is one of 81 researchers around the world
to receive a grant of $100,000 each through the foundation’s
Grand Challenges Explorations initiative, which aims to
develop a pipeline of creative ideas that could change the face
of global health. The projects focus on novel approaches to
prevent and treat infectious diseases, such as HIV, malaria,
tuberculosis, pneumonia, and diarrheal diseases.
Günzl’s research focuses on Trypanosoma brucei, the
parasite carried by the tsetse fly in Sub-Saharan Africa that
causes sleeping sickness. There are an estimated 500,000
cases each year, and in some African provinces, half of the
population is infected. Untreated, the disease is invariably
fatal. However, existing drugs are very toxic, too expensive,
difficult to administer, and/or not effective against all subspecies
UConn School of Medicine

Cato T. Laurencin, M.D., Ph.D.
Vice President for Health Affairs
Dean, School of Medicine
P.S. I would enjoy hearing from you.
I can be contacted at 860-679-2594
or laurencin@uchc.edu.

of the parasite. Moreover, resistance to existing drugs is on
the rise and vaccine development is not in sight. Thus, new
strategies to combat the parasite are urgently needed.
In light of the Gates Foundation grant, Günzl will be
able to concentrate on a unique trait of T. brucei. The
parasite lives freely in the human bloodstream and it
must continuously swim forward to evade immune
responses. Günzl will attempt to develop serumstable adhesive RNA molecules which immobilize
trypanosomes on human endothelial cells.
“It’s just an idea, I have no preliminary data,” says
Günzl. “From my previous research experience, I can see
where it may work but I can also think of reasons why it
might not work. But it is definitely worth trying.”
Günzl’s proposal to the Gates Foundation was only two
pages long, which differs greatly from the lengthy and dataproven proposals researchers need to submit to the National
Institutes of Health in order to receive grant money. “It’s
a nice thing for a scientist,” explains Günzl. “This grant is
allowing me to go and do something completely new and
unconventional, and that’s what can lead to big discoveries.”
For instance, if Günzl’s hunch proves true, it could lead to a
shortcut for a new treatment. The other funded researchers
will explore a wide range of new ideas, including giving
mosquitoes a “head cold” to prevent them from detecting and
biting humans; developing a tomato to deliver antiviral drugs;
and using a laser to enhance the effect of vaccines. Projects
that show promise are eligible for additional funding of
$1 million or more. n
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As you will see, I am
unabashedly proud of this
medical school and the entire
UConn Health Center. Please
spend a few minutes with the
newsletter and let me show
you why…

$4
Million
Grant
Studies Exercise as Aid to Quitting Smoking

C

heryl Oncken, M.D., associate professor of medicine, has received a five-year, $4 million
federal grant to study whether exercise can help older women quit smoking and improve
their overall health.
“Our goal is to study whether an exercise program can help postmenopausal women quit
smoking and abstain from cigarettes,” says Oncken, a nationally recognized expert on smoking
cessation, who received the grant from the National Institute on Drug Abuse.
“Most smoking research focuses on healthy women. Our study is looking at postmenopausal women who have greater risk of lower bone density, depression and
weight gain than younger women,” says Oncken.
About 30 percent of female smokers are postmenopausal, and the proportion is
expected to grow as the population ages. Smokers generally know about the harmful
effects of smoking and want to stop, but most people have a hard time quitting. “It
takes an average of three to five quit attempts to finally kick the habit,” says Oncken,
who has studied the use of various medications and behavioral therapies designed to
help people abstain. “Our goal is to find the most effective treatment or combination of
treatments to help people achieve their goal.”
The study will recruit about 300 postmenopausal women, all of whom will receive
behavioral counseling and the medication varenicline, and then be randomly assigned to either a
supervised exercise program or a supervised relaxation control program.
“We hypothesize that women in the exercise program will have greater abstinence rates at the
end of treatment and at the end of a year than women in the relaxation program,” says Oncken.
The researchers also hypothesize that the ameliorative effects of exercise on smoking cessation
and depression will improve abstinence rates among women with a history of depression equal
to those with no history of depression, and that exercise will improve smoking cessation by
reducing nicotine craving and by increasing self-confidence. n

v

ohn Taylor, III, M.D., a urologist,
researcher and assistant
professor of surgery at the
UConn School of Medicine, has
received a five-year, $729,000
research grant from the American
Cancer Society for his study of the
role of inflammatory molecules on
the development and progression
of bladder cancer.
“We currently have no markers
to determine which patients with
bladder cancer will have progression,
which patients would benefit from
early aggressive treatment, or
even which patients will respond
favorably to treatment,” Taylor says.
“Our early data are quite promising
and could lead to novel ways to
manage this disease.”
The grant is one of 27 research
projects the American Cancer
Society is funding in Connecticut,
totaling nearly $10 million.
“Virtually every major
development in cancer research in
the last half century can point to
a Society-funded researcher who
played a key role along the way,
with most of those investigators
getting Society support early in
their careers when funding
is particularly difficult
to get,” says Sarah
Shafir, American
Cancer Society
Connecticut vice
president of health
initiatives.
In 2005,
Taylor was one of
10 researchers in
the country to receive
a Dennis W. Jahnigen Scholars
Award from the American Geriatrics
Society. The two-year, $200,000
grant helped fund his work on agerelated changes in the bladder. n
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Two New Stem Cell Lines

U

Conn School of Medicine scientists recently made two new lines of human embryonic stem
cells available to academic researchers, joining an elite group of universities engaged in efforts
to create, characterize and distribute new human embryonic stem cell lines for research and
therapeutic purposes.
“Distribution of these new lines helps broaden the state’s growing stem cell research community,
and creates an additional supply of stem cells for research here and around the world,” says RenHe Xu, M.D., Ph.D., associate professor in the Department of Genetics and Developmental Biology
at the medical school, and director of the university’s Stem Cell Core Laboratory. The two new lines –
identified as CT1 and CT2 – were created last summer by Xu and Ge Lin, Ph.D., his colleague in
the core lab.
The university’s core facility was established in 2007 after the Connecticut legislature and
Gov. M. Jodi Rell set aside $100 million for embryonic and adult stem cell training and research
programs at state universities. UConn’s core lab is culturing, testing and banking both federally
approved and unapproved stem cell lines.
Because of the tendency for chromosomal abnormalities to increase with the cells’ age, or higher
passages, Xu’s team applied DNA sequencing technology to obtain a detailed analysis of the molecular

UConn School of Medicine

By creating and establishing the
two new human embryonic stem
cell lines, UConn joins an elite
group of universities engaged in
efforts to create, characterize and
distribute new human embryonic
stem cell lines for research and
therapeutic purposes.

signature of each cell line. “This established a genetic database for
our cell lines against which researchers can compare their work. It
helps them make sure any results they find are reliable,” says Xu.
Because the new Connecticut stem cell lines lack the genetic
mutations and chromosomal abnormalities that often occur and
accumulate in cell lines cultured and stored for a long time, they
are highly prized by researchers. And because the cells are stored
to await distribution after fewer than 15 passages – each passage
is about one week’s growth of the embryonic stem cell colonies
in vitro – they have greater research value. “Many scientists
seeking to understand how embryonic stem cells differentiate
need lines with low passage to guarantee a longer window
of opportunity to manipulate the cells. Because our lines are
younger, the scientists can work with them longer,” says Xu.
The two new Connecticut cell lines were derived from unused
embryos donated for research with informed, written consent by
patients of UConn’s Center for Advanced Reproductive Services.
The work also was reviewed and approved by the university’s
Embryonic Stem Cell Research Oversight Committee, a panel
that oversees work with human stem cells.
Besides creating the new lines, Xu and his team have been
very involved in training other researchers in the culture

Research

w

and use of human embryonic stem cells. “We have held 15
training classes and trained 100 scientists from UConn,
Wesleyan University, Yale University and the University of
Massachusetts.” In addition, UConn researchers are working
on more than 20 different projects designed to promote
understanding of the differentiation of stem cells and harness
their therapeutic potential.
“We are extremely fortunate to have a network of
investigators with expertise in human embryonic stem cell
culture methods, cell characterization methods and a core cell
production facility adjacent to clinician scientists working to
introduce stem cell therapies in medical practice,” says Marc
Lalande, Ph.D., senior associate dean for research planning and
coordination, professor and chair of the Department of Genetics
and Development Biology, and director of the university’s Stem
Cell Institute. “It is a unique collaboration that will help bring
the potential benefits of this research to fruition.” n

In June of 2005, Connecticut became only
the third state in the country to use its own
money to fund human embryonic stem cell
research. That pivotal decision helped to
keep Connecticut in the forefront of stem
cell research.

Understanding the Immune Response

U

sing laser scanning microscopy, Health Center researchers have examined the cell dynamics
of an immune response. By examining the spleens of mice infected with bacteria at different
times during the infection, the researchers learned that the immune response appeared to
begin in the lymphocyte-containing white pulp. A few days after the beginning of the immune
response, the T cells moved between the white pulp and the red blood cell rich red pulp areas
of the spleen through structures called “bridging channels.”
“Our study was designed to increase our understanding of the precise anatomical movement
of cells responding to a real infection,” says Leo Lefrançois, Ph.D., professor of immunology,
and one of the researchers involved in the study with graduate student Jeffrey McNamara
and Kamal Khanna, Ph.D., a Damon-Runyon fellow. “The study revealed for the first time the
anatomy of an ongoing immune response, information that could ultimately be used to help
develop better therapies for fighting infection or blocking the response in autoimmune disorders,”
says Lefrançois. Their research was published in a recent issue of Science. n

x
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Honors
Honors

Gifts

Fast Fact
Dr. Joseph Anderson, left, led a
new initiative to improve access to
colonoscopies among underserved
populations.

6

Percent of applicants accepted
into the UConn School of Medicine
Academic Year 2008-2009

Two Recent Honors: Laurencin Recognized for

A

Contributions to Biomedical and Tissue Engineering,
Receives Presidential Award for Mentoring

C

ato T. Laurencin, M.D., Ph.D., vice president for health
affairs and dean of the medical school, recently received
two prestigious honors related to bioengineering and
mentoring aspiring researchers.
In February, Laurencin was named the 2009 winner
of the Pierre Galletti Award, the highest honor bestowed
annually by the American Institute for Medical and Biological
Engineering. He was recognized for “seminal contributions to
tissue engineering and leadership in international biomedical
engineering.” Established in 1999, the award is presented
to an individual in recognition of his or her contributions to
public awareness of medical and biological engineering, and
to promotion of the national interest in science, engineering
and education.
In July, Laurencin was among a select group of science,
math and engineering educators named by President Barack
Obama to receive the Presidential Award for Excellence. Each
year, this award recognizes the crucial role that mentoring
plays in the academic and personal development of students
studying science or engineering.
“There is no higher calling than furthering the educational
advancement of our nation’s young people and encouraging
and inspiring our next generation of leaders,” President
Obama said in a White House statement.
Throughout his career, Laurencin has earned national
and international prominence as an orthopaedic surgeon
and chemical engineering expert. He holds the Health Center’s
Van Dusen Endowed Chair in Academic Medicine and is a
professor in the Department of Orthopaedic Surgery. He also
holds an appointment in the UConn School of Engineering
as a professor of chemical, materials and biomolecular
engineering. He is a fellow of the American Surgical
Association and the American Academy of Orthopaedic
Surgeons and was named one of the 100 engineers of the
modern era by the American Institute of Chemical Engineers.
Laurencin joined UConn in 2008 from the University
of Virginia where he was the Lillian T. Pratt Distinguished
Professor and chair of the Department of Orthopaedic
Surgery, the orthopaedic surgeon-in-chief at the University
of Virginia Health System and a university professor, one
of the university’s most prestigious titles. n

UConn School of Medicine

Kastner
Receives AMA Leadership Award

T

heodore A. Kastner, ’81, M.D., M.S., founder and
president of Developmental Disabilities Health Alliance
(DDHA), a New Jersey health care organization exclusively
for individuals with developmental disabilities, has been
named a recipient of the American Medical Association’s 2008
Leadership Award.
Kastner was among 56 individuals nationwide honored
by the AMA Foundation at its annual Excellence in Medicine
Awards ceremony. Recipients of the award are recognized for
demonstrating outstanding non-clinical leadership skills in
advocacy, community service and education.
Throughout his career, Kastner has focused on a chronically
underserved population: people with developmental
disabilities. DDHA began as a single office in 1997 serving 200
patients; today, it has six offices across New Jersey providing
comprehensive health care services to more than 3,000 patients
and health care management to 3,400 patients. n

Physician-Researcher Honored

Z

ihai Li, M.D., Ph.D., a prominent
physician-researcher and leader in
the field of immunotherapy, was
recently inducted into the American
Society for Clinical Investigation, one of
the nation’s oldest and most respected
medical honor societies.
Li’s research team has made seminal
contributions to understanding the
immunological properties of heat shock proteins (HSPs) in
cancer immunotherapy and immune tolerance. His work has
broad implications in understanding how the immune system
operates physiologically and how it might be harnessed for the
prevention and treatment of human diseases. n

y

Neag Gift Supports Imaging,
Treatment Upgrades

Improving Access to Colonoscopies

E

arlier this year, a statewide effort led by the UConn Health Center’s Colon Cancer
Prevention Program made colonoscopies available to uninsured and underinsured
Connecticut residents. The initiative provided colonoscopies to nearly 300 patients at no
cost to them, nearly 50 of them done by Joseph C. Anderson, M.D., at the UConn Health Center.
“The colonoscopy is a major prevention tool, but not everyone has access,” says Anderson,
the clinical director of the colon cancer prevention program and medical director for the
Connecticut project. “The more people we can screen, the more people we can help. Polyps in
the colon will become cancerous whether people have insurance or not.”
Unfortunately for those without insurance, the cost of the test, which can detect early signs
of cancer, generally places it out of their reach.
Using a grant of $950,000 from the state Department of Public Health, the Health Center
formed a partnership with federally funded community health centers and endoscopists
around the state to identify patients between the ages of 50 and 65 and provide them with
colonoscopies. The program provided follow-up services to participants.
“The goal is to promote, improve and optimize the appropriate use of high quality
colorectal cancer screening and follow-up services, and eliminate or decrease racial, ethnic
and socioeconomic disparities in access to these screenings,” says Jennifer Granger, chief
operating officer of the Community Health Center Association of Connecticut.
Colon cancer is the second most common cancer and the third leading cause of cancer
deaths in the nation. n

z

$3.8 million gift from
Carole and Ray Neag,
two of the university’s
most generous supporters, will
help the Health Center upgrade
its diagnostic, planning and
treatment services.
The first installment, a new
computerized tomography (CT)
scanner offering unprecedented
precision, speed and patient
comfort, arrived this spring.		
The new scanner uses “dualsource energy” technology, in
which two sources of radiation
are used to acquire information
and create a complex 3D image
of a patient’s anatomy. The
technology gives physicians and
researchers sophisticated images
not previously available.
The Neags’ gift also provides
for a high-dose radiation system
and a CT simulator which,
together with the scanner and the
TomoTherapy cancer treatment
system (provided by a previous
gift from the Neags), greatly
enhances research, education and
treatment at the Health Center.
“Its functionality for
cardiology alone will be leaps
and bounds beyond our existing
capabilities,” says Bruce Liang,
M.D., director of the Pat and Jim
Calhoun Cardiology Center.
Advantages of the new
scanner include clearer images, a
90 percent reduction in scanning
times and selective presentation
of a scanned image. The CT
simulator will enhance treatment
planning, and the high dose
rate brachytherapy will treat a
variety of cancers at the Neag
Comprehensive Cancer Center.
“Carole and I feel strongly
about the state and its university,
and believe the state’s flagship
research university should have
the very best if at all possible,”
says Ray Neag. n
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to promotion of the national interest in science, engineering
and education.
In July, Laurencin was among a select group of science,
math and engineering educators named by President Barack
Obama to receive the Presidential Award for Excellence. Each
year, this award recognizes the crucial role that mentoring
plays in the academic and personal development of students
studying science or engineering.
“There is no higher calling than furthering the educational
advancement of our nation’s young people and encouraging
and inspiring our next generation of leaders,” President
Obama said in a White House statement.
Throughout his career, Laurencin has earned national
and international prominence as an orthopaedic surgeon
and chemical engineering expert. He holds the Health Center’s
Van Dusen Endowed Chair in Academic Medicine and is a
professor in the Department of Orthopaedic Surgery. He also
holds an appointment in the UConn School of Engineering
as a professor of chemical, materials and biomolecular
engineering. He is a fellow of the American Surgical
Association and the American Academy of Orthopaedic
Surgeons and was named one of the 100 engineers of the
modern era by the American Institute of Chemical Engineers.
Laurencin joined UConn in 2008 from the University
of Virginia where he was the Lillian T. Pratt Distinguished
Professor and chair of the Department of Orthopaedic
Surgery, the orthopaedic surgeon-in-chief at the University
of Virginia Health System and a university professor, one
of the university’s most prestigious titles. n
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Kastner
Receives AMA Leadership Award

T

heodore A. Kastner, ’81, M.D., M.S., founder and
president of Developmental Disabilities Health Alliance
(DDHA), a New Jersey health care organization exclusively
for individuals with developmental disabilities, has been
named a recipient of the American Medical Association’s 2008
Leadership Award.
Kastner was among 56 individuals nationwide honored
by the AMA Foundation at its annual Excellence in Medicine
Awards ceremony. Recipients of the award are recognized for
demonstrating outstanding non-clinical leadership skills in
advocacy, community service and education.
Throughout his career, Kastner has focused on a chronically
underserved population: people with developmental
disabilities. DDHA began as a single office in 1997 serving 200
patients; today, it has six offices across New Jersey providing
comprehensive health care services to more than 3,000 patients
and health care management to 3,400 patients. n

Physician-Researcher Honored

Z

ihai Li, M.D., Ph.D., a prominent
physician-researcher and leader in
the field of immunotherapy, was
recently inducted into the American
Society for Clinical Investigation, one of
the nation’s oldest and most respected
medical honor societies.
Li’s research team has made seminal
contributions to understanding the
immunological properties of heat shock proteins (HSPs) in
cancer immunotherapy and immune tolerance. His work has
broad implications in understanding how the immune system
operates physiologically and how it might be harnessed for the
prevention and treatment of human diseases. n
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Neag Gift Supports Imaging,
Treatment Upgrades

Improving Access to Colonoscopies

E

arlier this year, a statewide effort led by the UConn Health Center’s Colon Cancer
Prevention Program made colonoscopies available to uninsured and underinsured
Connecticut residents. The initiative provided colonoscopies to nearly 300 patients at no
cost to them, nearly 50 of them done by Joseph C. Anderson, M.D., at the UConn Health Center.
“The colonoscopy is a major prevention tool, but not everyone has access,” says Anderson,
the clinical director of the colon cancer prevention program and medical director for the
Connecticut project. “The more people we can screen, the more people we can help. Polyps in
the colon will become cancerous whether people have insurance or not.”
Unfortunately for those without insurance, the cost of the test, which can detect early signs
of cancer, generally places it out of their reach.
Using a grant of $950,000 from the state Department of Public Health, the Health Center
formed a partnership with federally funded community health centers and endoscopists
around the state to identify patients between the ages of 50 and 65 and provide them with
colonoscopies. The program provided follow-up services to participants.
“The goal is to promote, improve and optimize the appropriate use of high quality
colorectal cancer screening and follow-up services, and eliminate or decrease racial, ethnic
and socioeconomic disparities in access to these screenings,” says Jennifer Granger, chief
operating officer of the Community Health Center Association of Connecticut.
Colon cancer is the second most common cancer and the third leading cause of cancer
deaths in the nation. n
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$3.8 million gift from
Carole and Ray Neag,
two of the university’s
most generous supporters, will
help the Health Center upgrade
its diagnostic, planning and
treatment services.
The first installment, a new
computerized tomography (CT)
scanner offering unprecedented
precision, speed and patient
comfort, arrived this spring.		
The new scanner uses “dualsource energy” technology, in
which two sources of radiation
are used to acquire information
and create a complex 3D image
of a patient’s anatomy. The
technology gives physicians and
researchers sophisticated images
not previously available.
The Neags’ gift also provides
for a high-dose radiation system
and a CT simulator which,
together with the scanner and the
TomoTherapy cancer treatment
system (provided by a previous
gift from the Neags), greatly
enhances research, education and
treatment at the Health Center.
“Its functionality for
cardiology alone will be leaps
and bounds beyond our existing
capabilities,” says Bruce Liang,
M.D., director of the Pat and Jim
Calhoun Cardiology Center.
Advantages of the new
scanner include clearer images, a
90 percent reduction in scanning
times and selective presentation
of a scanned image. The CT
simulator will enhance treatment
planning, and the high dose
rate brachytherapy will treat a
variety of cancers at the Neag
Comprehensive Cancer Center.
“Carole and I feel strongly
about the state and its university,
and believe the state’s flagship
research university should have
the very best if at all possible,”
says Ray Neag. n
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Director of New England
Musculoskeletal Institute
Is Named Fellow of AIMBE

T

he American Institute for Medical and
Biological Engineering has inducted Jay R.
Lieberman, M.D., an internationally recognized
joint replacement expert and director of the Health
Center’s New England Musculoskeletal Institute,
into its College of Fellows.
Lieberman, professor and chairman of the
Department of Orthopaedic Surgery and a member of
both the prestigious Hip Society and Knee Society, was
nominated for “significant and sustained contributions
to understanding the biology of arthroplasty implants,
and for innovative strategies for bone regeneration
using gene therapy and materials science,” according
to the AIMBE.

